The protein receptor for Clostridium botulinum type B neurotoxin was purified 340-fold from
rat synaptosomes by successive chromatography on DEAE-Sepharose, phenyl-Toyopearl, …

Protein kinase C-mediated phosphorylation of a 25-kDa synaptosome-associated protein (SNAP-25)
was examined in living PC12 cells. Phorbol 12-myristate 13-acetate treatment …

125 I‐labeled botulinum type B neurotoxin was shown to bind specifically to recombinant rat
synaptotagmins I and II. Binding required reconstitution of the recombinant proteins with …

Although the vesicular protein synaptotagmin I contains two Ca 2+ -binding domains (C 2 A
and C 2 B), Ca 2+ binding to the C 2 B domain is more important for triggering synchronous …

We have asked whether loss of the Ca 2+ sensor protein synaptotagmin I influences the
total amount of neurotransmitter released after a presynaptic action potential. Hippocampal …

New anti-cancer therapy with boron neutron capture therapy (BNCT) is based on the nuclear
reaction of boron-10 with neutron irradiation. The median survival of BNCT patients with …

Neurotransmitter release proceeds by Ca 2+ -triggered, SNARE-complex-dependent synaptic
vesicle fusion. After fusion, the ATPase NSF and its cofactors α- and βSNAP disassemble …

Mitochondria are important cellular organelles in most metabolic processes and have a highly
dynamic nature, undergoing frequent fission and fusion. The dynamic balance between …

Clostridium botulinumtype B neurotoxin (BoNT/B) recognizes a complex of synaptotagmin II
and ganglioside GT1b or GD1a as the high-affinity toxin binding site. Recombinant deletion …

Glioblastoma, a malignant brain tumor with poor disease outcomes, is managed in modern
medicine by multimodality therapy. Boron neutron capture therapy (BNCT) is an encouraging …